Merck – Talk Bio

Merck to Lay Off 6,000 Employees, Reduce Workforce by 8% in $3B Cost-Cutting Move

3 weeks ago talkbio0Tagged cost-cutting, Gardasil, Keytruda, layoffs, Merck, restructuring

Merck; layoffs; cost-cutting; restructuring; pharmaceuticals; job cuts; Keytruda; Gardasil; workforce reduction

Merck Terminates Midstage Asset from $1.9B Pandion Acquisition over Lack of Clinical Benefit

3 weeks ago talkbio0Tagged asset termination, Benefit, biotech acquisition, Clinical Trials, lack of, Merck, Pandion

Merck; Pandion Therapeutics; asset termination; clinical trial; lack of benefit; biotech acquisition

Merck Announces $3 Billion Cost-Cutting and Restructuring Plan

4 weeks ago talkbio0Tagged Drug Industry, estate, Financial cost, Keytruda, Merck, Q2 2025, restructuring, Transection (procedure)

Merck; cost cutting; restructuring; job cuts; real estate reduction; Keytruda; pharmaceutical industry; Q2 2025 financials

Sino Biopharm Acquires Merck’s PD-1xVEGF Bispecific Partner LaNova for up to $951M

1 month ago talkbio0Tagged Acquisition, Antibodies, Bispecific, Biopharm, Cancer Therapeutic Procedure, isononanoyl oxybenzene sulfonate, LaNova Medicines, Merck, PD-1xVEGF

Sino Biopharm; LaNova Medicines; acquisition; Merck; PD-1xVEGF bispecific antibody; cancer therapy; Chinese pharma; $951 million deal

Merck Makes $10B Acquisition of Verona Pharma to Bolster Respiratory Portfolio

1 month ago talkbio0Tagged Acquisition, COPD, Drug Industry, Keytruda patent, Merck, Ohtuvayre, Pharma, Respiration Disorders, Verona

Merck; Verona Pharma; acquisition; Ohtuvayre; COPD; respiratory disease; Keytruda patent; biotech; pharmaceutical industry

ACIP Backs Merck’s Enflonsia for RSV Prevention in Infants

2 months ago talkbio0Tagged ACIP, Children Program, Enflonsia, Immunization, Infant, Merck, Monoclonal Antibodies, Respiratory syncytial virus, RSV, Vaccines

ACIP; Merck; Enflonsia; RSV; monoclonal antibody; infants; immunization; Vaccines for Children Program

TIGIT Turmoil: How Pharma Burned Billions on Failed Immuno-Oncology Projects

2 months ago talkbio0Tagged Arcus Biosciences, Clinical Trials, Gilead, immuno-oncology, iTeos, Merck, Myers, Novartis, Pharma, Roche (company), SmithKline Beecham, squibb, TIGIT gene, Tiragolumab

TIGIT; immuno-oncology; failed clinical trials; pharma investment loss; Gilead; GSK; Bristol Myers Squibb; Novartis; Merck; Roche; iTeos; Arcus Biosciences; tiragolumab; belrestotug

Merck Wins FDA Approval for RSV Antibody Drug, Intensifying Market Competition

2 months ago talkbio0Tagged Approved, AstraZeneca, competition, Enflonsia, Infant, Market, Merck, Monoclonal Antibodies, Respiratory syncytial virus, sanofi, United States Food and Drug Administration

Merck; FDA approval; RSV; monoclonal antibody; infants; Enflonsia; competitive market; Sanofi; AstraZeneca

Merck’s Oral PCSK9 Inhibitor Enlicitide Significantly Reduces LDL Cholesterol in Phase 3 Trials

2 months ago talkbio0Tagged Administration of prophylactic statin, cholesterol, CORALreef, CORALreef AddOn, enlicitide, HeFH, Hypercholesterolemia, Familial, Hyperlipidemia, LDL-C, Merck, Oral Therapy, PCSK9 inhibitor

Merck; PCSK9 inhibitor; enlicitide; phase 3 trials; cholesterol; LDL-C; oral therapy; hyperlipidemia; familial hypercholesterolemia; CORALreef HeFH; CORALreef AddOn; statin therapy

Merck’s Enflonsia FDA Approval Spurs Sanofi to Accelerate Beyfortus Supply Ahead of 2025-26 RSV Season

2 months ago talkbio0Tagged Approved, AstraZeneca, Beyfortus, Enflonsia, Health care facility, Immunization, Infant, Merck, Respiratory syncytial virus, sanofi, supply chain, United States Food and Drug Administration

RSV; Infant immunization; Merck; Sanofi; Beyfortus; Enflonsia; FDA approval; supply chain; healthcare; AstraZeneca